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Outside pregnancy, both obesity and diabetes mellitus are associated with changes in inflammatory cyto-
kines. Obesity in pregnancy may be complicated by gestational diabetes mellitus (GDM) and/or fetal mac-
rosomia. The objective of this study was to determine the correlation between maternal cytokines and
fetomaternal adiposity in the third trimester in women where the important confounding variable
GDM had been excluded. Healthy women with a singleton pregnancy and a normal glucose tolerance test
at 28 weeks gestation were enrolled at their convenience. Maternal cytokines were measured at 28 and
37 weeks gestation. Maternal adiposity was assessed indirectly by calculating the Body Mass Index (BMI),
and directly by bioelectrical impedance analysis. Fetal adiposity was assessed by ultrasound measure-
ment of fetal soft tissue markers and by birthweight at delivery. Of the 71 women studied, the mean
maternal age and BMI were 29.1 years and 29.2 kg/m2 respectively. Of the women studied 32 (45%) were
obese. Of the cytokines, only maternal IL-6 and IL-8 correlated with maternal adiposity. Maternal TNF-a,
IL-b, IL-6 and IL-8 levels did not correlate with either fetal body adiposity or birthweight. In this well
characterised cohort of pregnant non-diabetic women in the third trimester of pregnancy we found that
circulating maternal cytokines are associated with maternal adiposity but not with fetal adiposity.
 2012 Published by Elsevier Ltd.1. Introduction is the main physiological mediator of the acute phase reaction. ItMaternal obesity based on Body Mass Index (BMI)P30.0 kg/m2
is associated with increased pregnancy complications and its prev-
alence is increasing worldwide [1–3]. Recent research has high-
lighted that adipose tissue is not merely a passive repository for
energy, but rather it is a highly active organ [4]. Outside pregnancy,
obesity has been associated with a number of circulating markers
of inflammation [5–7]. During pregnancy, increased inflammation
has been associated with pre-eclampsia and gestational diabetes
mellitus (GDM), both of which are complications associated epide-
miologically with maternal obesity [8,9].
Cytokines are proteins and peptides secreted by cells, which
modulate the intercellular actions of the cell. Cytokines are the re-
sult of enhanced leucocytic activity for immunosurveillance. They
serve to protect the fetus, but an inflammatory response can some-
times be harmful. Cytokines are produced in all the tissues of the
body. The placenta and membranes secrete a large number of
pro and anti-inflammatory cytokines and chemokines [10,11]. La-
bour itself leads to a release of cytokines.
The inflammatory cytokines include IL-6, TNF-a, IL-8, and IL-b.
IL-6 is a glycosylated protein molecule produced mainly by the
TH2 lymphocytes, but also by monocytes and macrophages. IL-6Elsevier Ltd.
+353 1 4085786.has been used as a diagnostic indicator of infections and inflamma-
tion. TNF-a is a non-glycosylated protein which is stimulated by
bacteria and is mainly produced by the T cells, monocytes, macro-
phages and neutrophils. IL-8 is a non-glycosylated protein which is
secreted by macrophages and monocytes. The main action of IL-8 is
chemotaxis of neutrophils to adhere to endothelium. It is essential
in fetal innate immunity as neutrophils are the first cells to appear
at the site of an infection.
Maternal obesity, GDM and preeclampsia have each been
shown to influence intrauterine growth [12,13]. There is, however,
a dearth of studies which have examined the relationship between
maternal cytokines and fetomaternal adiposity. Adipocytes in the
fetus begin to develop at around 15 weeks gestation. The number
and size both increase particularly in the third trimester when fetal
fat increase from 5 to 15% [14].
The objective of this study was to examine the correlation be-
tween maternal cytokines in the third trimester with both mater-
nal and fetal adiposity in a well characterised cohort where GDM
had been excluded by a diagnostic glucose tolerance test (GTT) at
28 weeks gestation.
2. Materials and methods
This was a prospective nested cohort study involving women
previously recruited as part of a larger study [15]. In the larger
Table 1
Characteristics of the study population (n = 71).
Maternal characteristics Frequency (%) Mean ± SD Range
Age (years) 29.1 ± 4.8 20.0–41.0
Parity 0.8 ± 0.9 0–3
Early pregnancy BMI (kg/m2) 29.2 ± 6.1 19.1–42.5
Prenatal smoking 16.9
Newborn characteristics
Gestational age at delivery (weeks) 40.3 ± 1.0 38.0–42.0
Birth weight (kg) 3.7 ± 0.5 2.7–4.8
Birth weightP 4.5 kg 5.6
Male sex 47.9
Obstetric outcomes
Hypertension
Gestational hypertension 7.0
Preeclampsia 4.2
Induction rate 32.4
Caesarean delivery 28.2
BMI: Body Mass Index
Table 2
Mean maternal and fetal body composition and biomarkers values at 28 and 37 weeks
gestation (n = 71).
Maternal 28 weeks 37 weeks
Weight (kg) 85.8 (17.1)a 90.2 (17.9)a
BMI (kg/m2) 31.5 (6.0)a 33.2 (6.2)a
Fat mass (kg) 32.9 (10.9)a 34.4 (10.9)a
Fat-free mass (kg) 52.8 (6.6)a 55.7 (7.8)a
IL-b (pg/ml) 0.8 (0.6) 0.9 (0.7)
IL-6 (pg/ml) 1.8 (1.4) 2.0 (1.0)
IL-8 (pg/ml) 5.0 (1.8) 6.1 (2.9)
TNF-a (pg/ml) 7.3 (1.8)b 7.8 (1.9)b
Fetal
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sented for their GTT at around 28 weeks gestation. To minimise
confounding variables, the study was confined to white European
women. Women with chronic medical problems that predispose
to abnormal intrauterine growth were excluded, as well as cases
of multiple pregnancy and known congenital fetal abnormalities.
Women with evidence of recent infection were also excluded. In-
formed written consent was obtained.
All the women recruited had an early pregnancy ultrasound
scan to confirm gestational age. In early pregnancy maternal
weight and height were measured digitally in a standardised
way, and the BMI was calculated. At recruitment, maternal body
composition and weight were measured using multifrequency
eight electrodes bioelectrical impedance analysis (BIA) (Tanita
MC 180 MA, Tokyo, Japan). At the GTT, a serum sample was taken
and within 1 h from collection the sample was centrifuged at
3500 rpm for 10 min at 4 C. The supernatant was collected in
0.5 ml aliquots and immediately stored at 70 C until assayed.
Fetal body composition was also evaluated by abdominal ultra-
sound by one operator (NF) using a transabdominal curved array
transducer on an ALOKA prosounda7. The fetal abdominal subcuta-
neous tissue was measured on the anterior abdominal wall in mil-
limetres anterior to the margins of the ribs, using magnification at
the level of the abdominal circumference [16]. The fetal midthigh
muscle thickness was measured at the level of the femur diaphysis
as the distance from the outer border of the femur to the inner
edge of the subcutaneous layer. The fetal midthigh subcutaneous
tissue measurement was calculated by subtracting the distance
from the outer border of the femur to the outer border of the sub-
cutaneous layer from the thigh muscle.
Women were asked to return between 36 and 39 weeks gesta-
tion for a follow up assessment. At this visit a serum blood sample
was taken and centrifuged and then the serum was stored at
80 C until assayed. Maternal body composition measurements
were repeated and an ultrasound scan was performed by the same
operator (NF) to measure fetal body composition. The clinical out-
comes of the pregnancy were obtained from the medical records.
Serum cytokine concentrations of IL-b, IL-6, IL-8 and TNF-a,
where investigated by multiplex immunoassay. All reagents and
samples were brought to room temperature before use and all plas-
ma samples were run in duplicate. MSD multiplex assays employ a
sandwich immunoassay format where capture antibodies are
coated in a patterned array, on the bottomof thewells of plate, these
multiplex assays can be used to detect up to 10 analytes in cell
supernatant, serum or tissue lysates. A seven point standard curve
is generated on each plate and samples are interrogatedwith a low-
er level of detection of 0.6 pg/ml as per manufacturer’s guidelines.
Statistical analysis was performed using SPSS version 15.0 (SPSS
Inc. Chicago, IL, USA). Relevant descriptive statistics (mean, stan-
dard deviation and percentages) were obtained for the study pop-
ulation. The paired sample t-test was used to detect changes in the
parameters between 28 and 37 weeks gestation. Based on a sample
size of 71, the analysis will have at least 80% power to detect a
change in mean scores of 0.35 standard deviations at a level of
5% significance. The one-way analysis of variance (ANOVA) was
used to detect differences between the groups. The relationship be-
tween maternal inflammatory markers and maternal and fetal
parameters was investigated by use of Pearson correlation coeffi-
cients. The study was approved by the Hospital Research Ethics
Committee.Abdominal circumference (mm) 242.1 (1.4)a 331.5 (1.8)a
Abdominal subcutaneous tissue (mm) 3.4 (0.7)a 6.5 (1.6)a
Midthigh muscle thickness (mm) 8.0 (1.8)a 10.3 (2.8)a
Midthigh subcutaneous tissue (mm) 2.8 (0.8)a 4.9 (1.3)a
a p < 0.001.
b p = 0.009.3. Results
In the larger study, 259 women were recruited and attended
their second assessment visit at 37 weeks gestation. Of thosewomen, 28 had an abnormal OGTT and were excluded from further
analysis [15]. From the resulting study population, 21 women with
normal BMI, 18 overweight women, 17 women with class 1 obesity
(BMIP 30.0 and < 35.0 kg/m2) and 15 women with class 2 and 3
obesity (BMIP 35.0 kg/m2) had inflammatory markers analysed
at 28 and 37 weeks gestation. The characteristics of this study pop-
ulation are outlined in Table 1.
The mean values for the maternal inflammatory markers at
both 28 and 37 weeks gestation are shown in Table 2. The increase
in maternal TNF-a levels between 28 and 37 weeks gestation was
statistically significant (p = 0.009). Although average maternal
IL-b, IL-6 and IL-8 levels increased between 28 and 37 weeks ges-
tation, this increase was not statistically significant. Maternal
weight, fat mass and fat-free mass increased between 28 and
37 weeks gestation (p < 0.001) (Table 2). The fetal abdominal cir-
cumference (AC), abdominal subcutaneous tissue, midthighmuscle
thickness and midthigh subcutaneous tissue ultrasound measure-
ments also increased between 28 and 37 weeks gestation
(p < 0.001) (Table 2).
At 28 weeks gestation, maternal IL-6 and IL-8 levels correlated
with maternal fat mass (r = 0.3 and 0.3; p = 0.005 and 0.028 respec-
tively). Maternal IL-b and TNF-a levels at 28 weeks gestation did
not correlate with any of the maternal parameters.
At 37 weeks gestation, maternal IL-b, IL-8 and TNF-a did not
correlate with any of the maternal parameters, but maternal IL-6
continued to correlate with maternal weight and fat mass
(r = 0.3, and 0.3; p = 0.011 and 0.010 respectively). Table 3 outlines
Table 3
Maternal biomarkers at 28 and 37 weeks gestation analysed by BMI category (n = 71).
At 28 weeks
gestation
Normal
BMI
(n = 21)
Overweight
(n = 18)
Class 1
obese
(n = 33)
Class 2 and 3
obese (n = 15)
IL-b (pg/ml) 0.6 (0.5) 0.9 (0.9) 1.0 (0.5) 1.0 (0.6)
IL-6 (pg/ml) 1.3 (0.7) 1.9 (1.1) 1.9 (0.8) 2.4 (2.6)
IL-8 (pg/ml) 4.9 (1.8) 4.8 (1.3) 5.7 (2.4) 7.9 (12.1)
TNF-a (pg/
ml)
7.3 (1.8) 7.3 (1.9) 7.2 (1.7) 7.2 (1.7)
At 37 weeks gestation
IL-b (pg/ml) 0.9 (0.8) 0.8 (0.5) 1.1 (0.8) 0.8 (0.4)
IL-6 (pg/ml) 1.5 (0.7) 2.0 (1.1) 2.2 (0.9) 2.2 (1.0)
IL-8 (pg/ml) 5.7 (2.6) 6.0 (3.6) 6.9 (2.7) 6.0 (2.8)
TNF-a (pg/
ml)
8.0 (2.2) 7.5 (2.2) 7.7 (1.8) 7.9 (1.5)
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and 37 weeks gestation analysed by BMI category. Maternal IL-b,
IL-6, IL-8 and TNF-a levels did not correlate with any of the fetal
body composition parameters at either 28 or 37 weeks gestation
and nor did they correlate with birthweight.
4. Discussion
Several studies have firmly established the strong association
between obesity and elevated inflammatory markers, leading to
the recognition of obesity as a state of chronic low grade inflamma-
tion [17–19]. Maternal obesity is associated with increased risk of a
variety of adverse outcomes [3]. In pregnancy, a few studies to date
suggest that obesity is associated with inflammation. We found
that maternal IL-6 and IL-8 levels correlate positively with mater-
nal adiposity in the third trimester of pregnancy independently of
GDM.
A study conducted in the United Kingdom on 47 women in the
third trimester of pregnancy also showed that pregnant obese
women have higher CRP and IL-6 levels compared to lean pregnant
women [7]. However, the study does not report on how the mater-
nal BMI was calculated, whether the women had a glucose toler-
ance test in the pregnancy and the gestation at which the
inflammatory markers were assessed.
Although TNF-a levels are elevated in non-pregnant obese
adults, we found that TNF-a levels do not correlate with maternal
adiposity [20,21]. Our findings are similar to those by a cross-sec-
tional study where 80 women had their serum inflammatory
markers measured in the second trimester of pregnancy and by
also another study where 53 lean and 68 obese women had their
inflammatory markers measured at term before labour [22,23].
We found that maternal TNF-a levels increase between 28 and
37 weeks gestation. A longitudinal American study where fifteen
women had body composition measurements on three occasions:
pregravid and during both early (12–14 weeks) and late (34–
36 weeks) pregnancy also found that maternal TNF-a levels in-
crease in late pregnancy [24]. Studies have shown the placenta to
be an important source of TNF-a with greatest production rates
evident in late gestation which explains the increase in TNF-a lev-
els [25]. Maternal IL-b, IL-6 and IL-8 levels did not change between
28 and 37 weeks gestation. A longitudinal study carried out in
Switzerland on 38 pregnant multiethnic women also found that
IL-b, IL-6 and IL-8 levels did not change in pregnancy and remained
consistently low [26]. They found that IL-b levels increased shortly
before labour, while IL-6 and IL-8 levels rose in labour.
The impact of maternal obesity on the offspring is substantial.
In the long-term there is increasing observational evidence sugges-
tive of in utero programming of offspring in an adverse maternal
environment. Epidemiological evidence has shown that babiesborn to obese mothers are more likely to be obese in childhood
and adulthood and have increased risk of cardiovascular disease
in later life [27–29]. We found that maternal IL-b, Il-6, IL-8 and
TNF-a levels do not correlate with fetal adiposity in women with
a normal GTT. An American study found an association between in-
creased fetal adiposity and maternal IL-6 [30]. In this study, 18
multiethnic women with a singleton pregnancy were recruited
and neonatal anthropometry was carried out within 24 h of deliv-
ery. The mean BMI of the study population was similar to that in
our study but, in the American study women with GDM were in-
cluded in the analysis.
We acknowledge that our study has a number of weaknesses.
Recruitment was by convenience rather than consecutive. As obes-
ity was an indication for a screening GTT, the number of obese wo-
men and, in particular, the number of women with moderate to
severe obesity is overrepresented compared with the general pop-
ulation [3]. This overrepresentation, however, did facilitate com-
parison with women in the normal BMI category. While the
numbers studied appear small they do compare favourably with
the numbers in previous studies and, in particular, the proportion
of women in previous studies with moderate to severe obesity.
An advantage of our study is that it is prospective and the pa-
tient population is well characterised. Specifically, women with
existing hypertension, prepregnancy or GDM have been excluded.
The study was confined to white European women with a singleton
pregnancy which avoids the confounding variables of ethnicity and
multiple pregnancies. All women had their pregnancy dated in the
first trimester which is important because gestational age is impor-
tant for timing the GTT and is a key determinant of fetal adiposity
measurements and birthweight. The calculation of BMI was based
on accurate measurement of weight and height and not on selfre-
porting which has been shown to result in the miscategorisation of
BMI values [31].
The study also included the novel use of fetal soft tissue mark-
ers to assess fetal adiposity and the use of advanced bioelectrical
impedance analysis to assess maternal body composition. Recent
studies have shown that BIA in pregnancy is reproducible and cor-
relates well with biomarkers of maternal adiposity and with clini-
cal outcomes [32–34].
Our results show that, as in nonpregnant obese adults, obesity
in pregnancy is associated with an inflammatory up-regulation.
However, in women with a normal GTT we found no correlation
between maternal inflammatory markers and fetal adiposity. Fur-
ther studies are required to confirm whether fetal cytokines are
associated with fetal adiposity, in women where GDM has been
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